Factor H-Binding Fusion Protein Coating for Complement Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for methods and compositions to selectively bind complement components, particularly human complement factor H (CFH), to solid supports and modulate complement activity, as an improperly regulated complement system can cause damage to host or self-cells and exacerbate various diseases.
Innovation Solution
A fusion protein with a structure A-L-B, where A comprises a sequence similar to human serum albumin (SEQ ID NO:1) and B comprises a sequence similar to Streptococcus pneumoniae PspC, connected by a linker or chemical bond, is used to bind CFH and modulate complement activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a fusion protein combines human serum albumin and PspC sequences, then binding affinity to CFH is improved, but protein stability and solubility may deteriorate
Solution Approach 1:
The fusion protein is divided into distinct functional segments: the PspC portion (amino acids 69-148) responsible for CFH binding, the linker region, and the human serum albumin portion (amino acids 25-609) providing structural stability. This segmentation allows each domain to fulfill its specific function while maintaining overall protein integrity.
Solution Approach 2:
A linker region serves as an intermediary element between the PspC binding domain and the human serum albumin structural domain. This linker facilitates the transition between different functional requirements, allowing the protein to maintain both high CFH binding affinity and structural stability without direct conflict between the two domains.
2Reliability
If the fusion protein is used to bind CFH irreversibly, then complement modulation activity is improved, but potential harmful effects on host cells may increase
Solution Approach 1:
The fusion protein exhibits local quality differentiation where the PspC domain provides strong CFH binding activity, while the human serum albumin domain provides biocompatibility and reduces non-specific interactions. This localized functional distribution allows effective complement modulation without widespread harmful effects on host cells.
Solution Approach 2:
The fusion protein utilizes the natural binding properties of PspC to CFH and the structural stability of human serum albumin to create a self-regulating system that selectively modulates complement activity without requiring external intervention or causing broad host cell damage.
3Measurement precision
If a truncation of PspC is used instead of full-length protein, then binding specificity to CFH is improved, but binding strength may deteriorate
Solution Approach 1:
The fusion protein uses a truncated PspC sequence (amino acids 69-148) that provides sufficient CFH binding specificity without requiring the full-length PspC protein. This partial action approach achieves the necessary binding strength and specificity by selecting the critical functional region while eliminating redundant sequences.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fusion protein effectively recruits factor H from the blood, reducing complement activation on surfaces and decreasing inflammatory reactions associated with medical devices, and can treat diseases related to aberrant complement activity.
Implementation Method 1
The fusion protein effectively recruits factor H from the blood
Implementation Method 2
reducing complement activation on surfaces
Data Source
Figure 1
Figure 2~3
Figure 4
AI summary
A fusion protein of human serum albumin to Streptococcus pneumoniae PspCN, which binds complement factor H, is provided. The fusion protein has a structure A-L-B, wherein: A comprises a sequence that has at least 90% similarity to SEQ ID NO :1 (amino acids 25-609 of human serum albumin, HSA); L comprises a linker or a chemical bond; B comprises a sequence that has at least 90% similarity to SEQ ID NO:2 (amino acids 69-148 of PspC from the TIGR4 strain of Streptococcus pneumoniae). Also provided are medical devices, especially for use in haemodialysis, at least partially coated with the fusion protein and uses of the fusion protein.